|
Published by: Global Markets Direct
Published: Aug. 31, 2012 - 219 Pages
Table of Contents- Introduction
- Global Markets Direct Report Coverage
- Osteoarthritis Overview
- Therapeutics Development
- An Overview of Pipeline Products for Osteoarthritis
- Osteoarthritis Therapeutics under Development by Companies
- Osteoarthritis Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Osteoarthritis Therapeutics – Products under Development by Companies
- Osteoarthritis Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Osteoarthritis Therapeutics Development
- Johnson & Johnson
- Abbott Laboratories
- Osiris Therapeutics, Inc.
- AlphaRx, Inc.
- Antares Pharma, Inc.
- Sanofi-Aventis
- A.P. Pharma, Inc.
- TiGenix NV
- Cephalon, Inc.
- Dong-A Pharmaceutical Co., Ltd.
- Pfizer Inc.
- TransPharma Medical Ltd.
- Menarini Group
- Merck KGaA
- Bone Medical Limited
- Addex Pharmaceuticals
- Can-Fite BioPharma Ltd.
- Medivir AB
- Mesoblast Ltd
- Calzada Limited
- NicOx SA
- Osteologix, Inc.
- CombinatoRx, Incorporated
- Yuhan Corporation
- WhanIn Pharmaceutical Co., Ltd.
- XOMA Ltd.
- Galapagos NV
- MediPost Co., Ltd.
- CrystalGenomics, Inc.
- AnaMar Medical AB
- Jenrin Discovery, Inc.
- Amura Holdings Ltd.
- Asahi Kasei Pharma
- PLx Pharma Inc.
- TissueGene, Inc.
- Iroko Pharmaceuticals, LLC
- Winston Pharmaceuticals, Inc.
- Centocor Ortho Biotech, Inc.
- TOKUHON Corporation
- Cellceutix Pharmaceuticals, Inc.
- Flexion Therapeutics
- Stempeutics Research Private Limited
- Ampio Pharmaceuticals, Inc.
- Osteoarthritis – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- Sprifermin - Drug Profile
- PMX53 - Drug Profile
- Chondrogen - Drug Profile
- Indaflex - Drug Profile
- mPGES-1 Inhibitor - Drug Profile
- CR 3719 Series - Drug Profile
- CR 4144 Series - Drug Profile
- CR 4152 Series - Drug Profile
- CR 4153 Series - Drug Profile
- CR 4167 Series - Drug Profile
- CR 3663 Series - Drug Profile
- CF 101 - Drug Profile
- AOD9604 - Drug Profile
- ST04 - Drug Profile
- Naproxcinod - Drug Profile
- Naproxcinod - Drug Profile
- TG-C - Drug Profile
- CG100649 - Drug Profile
- JD-4000 Series - Drug Profile
- KM 278 - Drug Profile
- Cartistem - Drug Profile
- Synavive - Drug Profile
- MIV-710 - Drug Profile
- Duexis - Drug Profile
- CR 5259 Series - Drug Profile
- APF-505 - Drug Profile
- CR 5790 Series - Drug Profile
- CR 4174 Series - Drug Profile
- AP-159 - Drug Profile
- MIV-711 - Drug Profile
- JNJ-39439335 - Drug Profile
- Capsitonin - Drug Profile
- Adalimumab - Drug Profile
- Civanex - Drug Profile
- Autologous Bone Marrow Mesenchymal Stem Cells Transplantation - Drug Profile
- Curcuma Domestica Extracts - Drug Profile
- Derris Scandens Benth Extracts - Drug Profile
- SI-000413 - Drug Profile
- PL 1100 Ibuprofen - Drug Profile
- XOMA 052 - Drug Profile
- Teriparatide - Drug Profile
- Autologous Stem Cell Transplantation - Drug Profile
- Methotrexate - Drug Profile
- Hydroxychloroquine - Drug Profile
- Sodium Hyaluronate - Drug Profile
- Hydrocortisone - Drug Profile
- SAR113945 - Drug Profile
- SAR113945 - Drug Profile
- Fasitibant - Drug Profile
- Platelet Rich Plasma - Drug Profile
- DAR Project - Drug Profile
- A2A PAM - Drug Profile
- Piroxicam - Drug Profile
- Corticosterone + Hyaluronic Acid - Drug Profile
- RNS60 - Drug Profile
- TT-063 - Drug Profile
- AM-3701 - Drug Profile
- AM-3876 - Drug Profile
- Dextrose - Drug Profile
- IP 880 - Drug Profile
- DLX105 - Drug Profile
- OTX-CP07 - Drug Profile
- FX005 - Drug Profile
- PF-05089771 - Drug Profile
- Ampion - Drug Profile
- Stempeucel- OA - Drug Profile
- ViaDor-Calcitonin - Drug Profile
- RepliCart - Drug Profile
- Cx-603 - Drug Profile
- AK150 - Drug Profile
- AIK1 - Drug Profile
- AIK-3 - Drug Profile
- OTX-CP03 - Drug Profile
- Drug For Immunology - Drug Profile
- Longanoid - Drug Profile
- WIP-901 - Drug Profile
- ABT-981 - Drug Profile
- IP 890 - Drug Profile
- AP-1531 - Drug Profile
- Osteoarthritis Therapeutics – Drug Profile Updates
- Osteoarthritis Therapeutics – Discontinued Products
- Osteoarthritis Therapeutics - Dormant Products
- Osteoarthritis – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Osteoarthritis, H2 2012
- Products under Development for Osteoarthritis – Comparative Analysis, H2 2012
- Number of Products under Development by Companies, H2 2012
- Number of Products under Development by Companies, H2 2012 (Contd..1)
- Number of Products under Development by Companies, H2 2012 (Contd..2)
- Number of Products under Development by Companies, H2 2012 (Contd..3)
- Number of Products under Investigation by Universities/Institutes, H2 2012
- Comparative Analysis by Late Stage Development, H2 2012
- Comparative Analysis by Mid Clinical Stage Development, H2 2012
- Comparative Analysis by Early Clinical Stage Development, H2 2012
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012
- Products under Development by Companies, H2 2012
- Products under Development by Companies, H2 2012 (Contd..1)
- Products under Development by Companies, H2 2012 (Contd..2)
- Products under Development by Companies, H2 2012 (Contd..3)
- Products under Development by Companies, H2 2012 (Contd..4)
- Products under Investigation by Universities/Institutes, H2 2012
- Johnson & Johnson, H2 2012
- Abbott Laboratories, H2 2012
- Osiris Therapeutics, Inc., H2 2012
- AlphaRx, Inc., H2 2012
- Antares Pharma, Inc., H2 2012
- Sanofi-Aventis, H2 2012
- A.P. Pharma, Inc., H2 2012
- TiGenix NV, H2 2012
- Cephalon, Inc., H2 2012
- Dong-A Pharmaceutical Co., Ltd., H2 2012
- Pfizer Inc., H2 2012
- TransPharma Medical Ltd., H2 2012
- Menarini Group, H2 2012
- Merck KGaA, H2 2012
- Bone Medical Limited, H2 2012
- Addex Pharmaceuticals, H2 2012
- Can-Fite BioPharma Ltd., H2 2012
- Medivir AB, H2 2012
- Mesoblast Ltd, H2 2012
- Calzada Limited, H2 2012
- NicOx SA, H2 2012
- Osteologix, Inc., H2 2012
- CombinatoRx, Incorporated, H2 2012
- Yuhan Corporation, H2 2012
- WhanIn Pharmaceutical Co., Ltd., H2 2012
- XOMA Ltd., H2 2012
- Galapagos NV, H2 2012
- MediPost Co., Ltd., H2 2012
- CrystalGenomics, Inc., H2 2012
- AnaMar Medical AB, H2 2012
- Jenrin Discovery, Inc., H2 2012
- Amura Holdings Ltd., H2 2012
- Asahi Kasei Pharma, H2 2012
- PLx Pharma Inc., H2 2012
- TissueGene, Inc., H2 2012
- Iroko Pharmaceuticals, LLC, H2 2012
- Winston Pharmaceuticals, Inc., H2 2012
- Centocor Ortho Biotech, Inc., H2 2012
- TOKUHON Corporation, H2 2012
- Cellceutix Pharmaceuticals, Inc., H2 2012
- Flexion Therapeutics, H2 2012
- Stempeutics Research Private Limited, H2 2012
- Ampio Pharmaceuticals, Inc., H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
- Osteoarthritis Therapeutics – Drug Profile Updates
- Osteoarthritis Therapeutics – Discontinued Products
- Osteoarthritis Therapeutics – Discontinued Products (Contd..1)
- Osteoarthritis Therapeutics – Dormant Products
- Osteoarthritis Therapeutics – Dormant Products (Contd..1)
- Osteoarthritis Therapeutics – Dormant Products (Contd..2)
- Osteoarthritis Therapeutics – Dormant Products (Contd..3)
- Osteoarthritis Therapeutics – Dormant Products (Contd..4)
- Osteoarthritis Therapeutics – Dormant Products (Contd..5)
- List of Figures
- Number of Products under Development for Osteoarthritis, H2 2012
- Products under Development for Osteoarthritis – Comparative Analysis, H2 2012
- Products under Development by Companies, H2 2012
- Products under Investigation by Universities/Institutes, H2 2012
- Late Stage Products, H2 2012
- Mid Clinical Stage Products, H2 2012
- Early Clinical Stage Products, H2 2012
- Discovery and Pre-Clinical Stage Products, H2 2012
- Assessment by Monotherapy Products, H2 2012
- Assessment by Combination Products, H2 2012
- Assessment by Route of Administration, H2 2012
- Assessment by Stage and Route of Administration, H2 2012
- Assessment by Molecule Type, H2 2012
- Assessment by Stage and Molecule Type, H2 2012
AbstractOsteoarthritis – Pipeline Review, H2 2012
Summary
Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H2 2012', provides an overview of the Osteoarthritis therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. 'Osteoarthritis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope- A snapshot of the global therapeutic scenario for Osteoarthritis.
- A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Osteoarthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Osteoarthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Get full details about this report >>
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
